Philippines President Defies Public Health, Allows E-Cigarette Bill to Expire

Aug.08.2022
Philippines President Defies Public Health, Allows E-Cigarette Bill to Expire
The Philippines' proposed e-cigarette law facing opposition from health officials and advocates for public health.

On his first day in office, Philippine President Marcos vetoed the bill to establish the special ecological zone at the Bura-gan airport city, sending a message that public interest should prevail over commercial profits.


However, the proposed Nicotine and Non-Nicotine Aerosol Products Regulation Act appears to be anything but. The President allowed the act to lapse on July 25th. While the e-cigarette bill would expand its market base and bring more funding to the tobacco industry, it is seen as harmful to health because it would allow individuals as young as 18 to buy, use, and sell e-cigarettes and heated tobacco products, and would lift flavor restrictions on e-cigarette liquids.


The National Health, Food and Drug Administration, Ministry of Education, Ministry of Finance, as well as dozens of medical associations and former health ministers, are strongly lobbying against an electronic cigarette bill. They believe that this puts the country's youth at risk of harmful effects from electronic cigarettes. Former health minister Francisco Duque opposed the claim that electronic cigarettes can help people quit smoking. He said that they typically have the opposite effect as they lead people to engage in more bad habits such as drinking and illegal drug use.


The Philippines is one of the countries with the highest smoking rates among adults and youth around the world. The Global Adult Tobacco Survey in 2015 revealed that nearly 23.8% of Filipino adults used some form of tobacco, with 22.7% of the population being smokers and 18.7% of them being daily smokers.


Approximately 117,000 people die each year in the country due to tobacco-related illnesses such as lung cancer and cardiovascular disease. The cost of treating the four main diseases caused by tobacco use in the Philippines is estimated to be 46.4 billion pesos.


Child rights activists and tobacco control advocates believe that the e-cigarette bill is a "victory for tobacco capital.


The public interest law organization, ImagineLaw, has stated that allowing this bill to become law would be a "betrayal of public health" and a "regrettable development" in light of President Marcos' promise to rebuild the country better.


When the President does not take action after receiving a legislative measure for 30 days, the legislation expires. The previous Congress shelved the e-cigarette bill for five months and on June 24th forwarded a registered copy to Malacañang, just six days before then-President Rodrigo Duterte's term ended.


Health experts and tobacco control advocates are calling for the rejection of the proposed bill, as its provisions conflict with public health goals and international standards, particularly in light of the Supreme Court's ruling in late June upholding the FDA's jurisdiction over tobacco products and reaffirming the country's commitment to the World Health Organization's Framework Convention on Tobacco Control.


Marcos hails from the Ilocos region where tobacco is the main cash crop. Allowing the electronic cigarette bill to expire puts narrow interests ahead of the common good.


Some are calling for the immediate convening of the Legislative-Executive Development Advisory Council (LEDAC) by the President and have pointed out that while the veto power is within the President's rights, its frequent use may strain relations between the executive and legislative branches of government.


In the coming days when meeting with congressional leaders, it should be clear that they will prioritize legislation that serves the public interest, rather than industry profits. The public interest should never be relegated to a secondary position.


Statement:


This article is compiled from third-party information and is intended for industry exchange and learning only.


This article does not represent the viewpoint of 2FIRSTS, and 2FIRSTS cannot confirm the truth or accuracy of the article's content. The compilation of this article is only intended for communication and research within the industry.


Due to limitations in the compiler's ability, the translated article may not fully convey the original meaning. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
JTI Research Finds 31% of UK Respondents Offered Illicit Tobacco, While 63% of Ennis Packs Lack Duty Marks
JTI Research Finds 31% of UK Respondents Offered Illicit Tobacco, While 63% of Ennis Packs Lack Duty Marks
Multiple JTI-backed studies in the UK and Ireland indicate that illicit tobacco remains visible across consumer interactions and local markets. In the UK, JTI research found that 31% of respondents said they had been offered illicit tobacco products. In Ireland’s Ennis area, a JTI-commissioned empty pack survey found that 63% of sampled cigarette packs did not carry Irish duty-paid markings. The findings come from industry research rather than official government estimates of illicit tobacco market size, but highlight continued concerns among regulators, legitimate retailers and tobacco companies over illicit trade.
Aug.19
EU Trade Department Faces Scrutiny Over Contacts With Tobacco Industry
EU Trade Department Faces Scrutiny Over Contacts With Tobacco Industry
European Ombudswoman Teresa Anjinho has opened an inquiry into how the European Commission’s Directorate-General for Trade handles interactions with the tobacco industry. The case follows a complaint from a civil society organisation that alleges regular, unnecessary and non-transparent contacts between DG TRADE and tobacco industry representatives, raising questions over compliance with the EU’s obligations under the WHO Framework Convention on Tobacco Control. The inquiry remains ongoing, and the Ombudswoman has not reached any finding of maladministration.
Aug.24
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Switzerland Tightens Vape Checks as Only 3 of 32 Tested Products Meet New Tobacco Rules
Switzerland Tightens Vape Checks as Only 3 of 32 Tested Products Meet New Tobacco Rules
According to Swiss media outlet Blick, local authorities are strengthening compliance checks on vape products, nicotine pouches and other tobacco-related products following the implementation of Switzerland’s revised Tobacco Products Act. A Basel laboratory tested 32 disposable vapes and e-liquids, with only three meeting regulatory requirements and 21 products banned from sale. Swiss authorities are also expanding retail inspections, laboratory testing and youth purchase checks to enforce the new tobacco and nicotine product rules.
Aug.12